Diabetes drugs linked to slower frailty progression in older adults
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2)…
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
If approved, investigational semaglutide 7.2 mg injection would offer the optionality of a higher dose for greater weight…
Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis | BMC Gastroenterology
Elangovan A, Shah R, Ali SM, Katz J, Cooper GS. High burden of obesity and low rates of…
Study compares GLP-1 drug benefits and finds substantial variation in clinical effects
A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes…
Weight-loss drugs: From a trickle to a flood
It’s been varyingly called the “fat shot”, “skinny jab” or “magic pill” by politicians and celebrities who’ve put…
Prices of Ozempic vs Mounjaro vs Wegovy: How much they cost in the US, UK, India and around the world |
Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However,…
WHO reviews highlight limited long-term data on GLP-1 drug safety
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies…
Karan Johar’s Ozempic joke: What you ought to know about weight loss drug
Ozempic 101: Is it behind Karan Johar’s weight loss? Fact sheet for health enthusiasts on benefits and risks…
Resalis Therapeutics Reports Durable, Fat-Selective Weight
Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Ozempic coming soon to India: What is it? Benefits, side effects and controversies
India’s drug controller, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic (semaglutide) on 26 September for use…